Invion (ASX:IVX) closes H1 with key R&D milestones for cancer and infectious diseases

Highlights,VRX Silica has executed a letter of intent (LOI) with ResourcesWA to explore a proposed power supply solution for the company’s Arrowsmith North Silica Sand Project.,Under the LOI, the company will analyse the potential to set up ...

Highlights,The SRN stock jumped over 20 per cent on 07 March 2023.,Ticking off a major upgrade, Surefire Resources has announced the Exploration Target Estimate (ETE) for the Victory Bore vanadium project.,The ETE has been derived as a lowe ...

Highlights,Wooboard’s key highlight of the reported period is the new improvements to its Sixty wellness app.,The app added new features like Vimeo-powered live streaming, new chat system, and Spanish-language support.,WOO also retains its ...

Highlights,Australia's WooBoard, a listed entity, has announced issuance of convertible notes worth AU$1 million,The terms include 6% p.a. coupon rate, which is payable after the end of the term (18 months),Clee Capital is the lead manager, ...

Highlights,Radiopharm Theranostics is developing a world‐class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.,For the first half ended 31 December, the company has reported encouragin ...

Highlights,Carbonxt performed maintenance and installation programs at its existing facilities during the first half, expected to boost its margin growth in 2023.,The company achieved crucial near-term objectives concerning its strategic KC ...

Highlights,Chimeric Therapeutics’ CHM 1101 (CLTX CAR T) therapy is undergoing trial at the City of Hope,This cell therapy is being designed to treat glioblastoma by Chimeric, Australia’s leader in cell therapy,The third dose cohort was comp ...

Highlights,Radiopharm Theranostics (ASX:RAD) is joining hands with Pharma15, a next-gen preclinical platform for therapeutic radiopharmaceuticals.,With this acquisition, the company will further improve its access to strong academic network ...

Highlights,Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab.,The study is focused on measuring ...

Highlights,CLU has completed the bookbuild to raise approximately AU$8.2 million (Placement and Institutional Entitlement),Retail Entitlement Offer would open next week on 8th March to raise up to AU$2.4 million,CLU, the online tutoring lea ...